Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14266197 | 0.85 | RAB9A (0.46) | USP2MEN1KMT2ALMNAPOLB | |
| SCHEMBL23411785 | 0.82 | MPO (0.46) | MPOHTR1ASLC6A2SLC6A4MEN1 | |
| SCHEMBL7965987 | 0.79 | HTR2C (0.49) | HTR2CCYP1A2HSD17B10MPOHTR1A | |
| SCHEMBL7966615 | 0.79 | LMNA (0.46) | HTR2CMPOHTR1ASLC6A2SLC6A4 | |
| SCHEMBL204714 | 0.77 | PARP1 (0.51) | — | |
| SCHEMBL7966015 | 0.77 | HTR2C (0.46) | HTR2CUSP2MPOHTR1ASLC6A2 | |
| SCHEMBL373400 | 0.75 | MPO (0.54) | USP2MPOMEN1KMT2ALMNA | |
| SCHEMBL20135667 | 0.73 | MPO (0.42) | HTR2CMPOMEN1KMT2AGABRA1 | |
| SCHEMBL29688843 | 0.73 | MPO (0.42) | HTR2CMPOMEN1KMT2AGABRA1 | |
| SCHEMBL2708939 | 0.71 | MPO (0.59) | HTR2CHSD17B10MPOPOLBGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
| CN-107922347-A | New imide derivative and its purposes as medicine | 田边三菱制药株式会社 | 2018-04-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | HTR2C 3534/4885CYP1A2 491/4885HSD17B10 1345/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | HTR2C 3675/4885CYP1A2 409/4885HSD17B10 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.